Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | PARP1 | P09874 | 3/20 | 0.54 |
| ▸ | TSHR | P16473 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | MMP8 | P22894 | 5/20 | 0.47 |
| ▸ | MMP13 | P45452 | 5/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14073116 | 0.85 | PARP1 (0.62) | PARP1TSHRKMT2AMMP8MMP13 | |
| SCHEMBL14073607 | 0.83 | MAPT (0.54) | PARP1KMT2AMAPT | |
| SCHEMBL14073260 | 0.83 | TSHR (0.60) | PARP1TSHRKMT2AMMP8MMP13 | |
| SCHEMBL14073354 | 0.80 | TSHR (0.55) | PARP1TSHRKMT2AMMP8MMP13 | |
| SCHEMBL14073044 | 0.80 | TSHR (0.73) | HTTPARP1TSHRKMT2AHSD17B10 | |
| SCHEMBL14073051 | 0.79 | PARP1 (0.70) | PARP1TSHRKMT2AMMP8MMP13 | |
| SCHEMBL14073212 | 0.78 | PKM (0.59) | PARP1TSHRKMT2AMMP8MMP13 | |
| SCHEMBL14073196 | 0.78 | HPGD (0.64) | PARP1TSHRKMT2AL3MBTL1 | |
| SCHEMBL14073090 | 0.78 | PARP1 (0.55) | PARP1TSHRKMT2AMMP8MMP13 | |
| SCHEMBL14073166 | 0.77 | PARP1 (0.57) | PARP1TSHRKMT2AMMP8MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080221093-A1 | Metalloprotease inhibitors containing a heterocyclic moiety | ALANTOS PHARMACEUTICALS HOLDING, INC. | 2008-09-11 | — | — | US | disclosed |
| US-20080221093-A1 | Metalloprotease inhibitors containing a heterocyclic moiety | ALANTOS PHARMACEUTICALS HOLDING, INC. | 2008-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221093-A1 | Metalloprotease inhibitors containing a heterocyclic moiety | MMP12, MMP13, MMP25 | THRB 4845/4885HTT 1630/4885PARP1 327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.